
{
  "documentMetadata": {
    "title": "Pneumonia, Klebsiella sp.",
    "lastUpdated": "2025-01-08",
    "sourceFile": "Pneumonia, Klebsiella sp..pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Signs and symptoms of pneumonia.",
        "Healthcare-associated pneumonia (HCAP) or hospital-acquired pneumonia (HAP) infection.",
        "Alcoholism and liver disease are risk factors for community-acquired pneumonia (CAP) infection.",
        "Empiric and definitive therapy",
        "See also: Klebsiella sp. for more information on treatment of infection due to antibiotic resistant strains"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Klebsiella pneumoniae",
        "Other Klebsiella spp."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "Klebsiella reported but in vitro susceptibility is pending:",
        "Infection of mild severity, host not immunocompromised, low suspicion of ESBL-producer or MDR organism",
        "Ceftriaxone 2 gm IV q24h if under age 60; 1 gm IV if over age 60",
        "Ciprofloxacin 400 mg IV q12h or 750 mg po bid or Levofloxacin 750 mg po/IV q24h",
        "In Critical Care unit and/or immunocompromised, possible MDR",
        "Meropenem 1-2 gm IV q8h",
        "Specific therapy based on culture and in vitro susceptibility results:",
        "Susceptible to ceftriaxone, ceftazidime, fluoroquinolones",
        "Ceftriaxone 2 gm IV q24h if under age 60; 1 gm IV if over age 60 OR",
        "Ciprofloxacin 400 mg IV q12h or 750 mg po bid or Levofloxacin 750 mg po/IV q24h>",
        "Resistant to ceftriaxone, ceftazidime (ESBL producing organism)",
        "Ertapenem 1 gm IV q24h OR Meropenem 2 gm IV q8h",
        "Carbapenem-resistant organism, likely serine carbapenemase",
        "Ceftazidime-avibactam 2.5 gm IV q8h OR",
        "Meropenem-vaborbactam 4.0 gm (2 gm Meropenem + 2 gm Vaborbactam) IV over 3 hr and administered every 8 hrs",
        "For suspected or proven producer of metallo-beta-lactamase, concomitant resistance resistant to all beta-lactams, fluoroquinolones, aminoglycosides and TMP/SMX",
        "No proven effective therapy, infectious diseases consultation strongly recommended."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "Susceptible to ceftriaxone and ceftazidime",
        "Piperacillin-tazobactam 4.5 gm IV (over 4 hr) q8h",
        "Cefepime 2 g IV q8h",
        "TMP-SMX 10 mg/kg of trimethoprim component in 2-3 divided doses per day",
        "Resistant to ceftriaxone, ceftazidime (ESBL producing organism)",
        "Ceftolozane-tazobactam 1.5 gm IV q8h (see Comments)",
        "Carbapenem-resistant organism, suspected metallo-betalactamase producer, concomitant resistance resistant to all beta-lactams, fluoroquinolones, aminoglycosides and TMP/SMX",
        "Ceftazidime-avibactam 2.5 gm IV q8h infused over 3h + Aztreonam 2 gm q6h IV infused over 3 h (see Comments) OR",
        "Cefiderocol 2 gm IV over 3 hrs q8h (complicated UTI) (See Comments)"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Duration of therapy is not well-defined. 10-14 days is typical, although shorter courses (e.g. 8-10 days) may be sufficient for patients with rapid resolution of signs and symptoms of pneumonia and drug-susceptible organisms. Longer courses (e.g., 3-4 weeks) may be needed for complicated cases (e.g., empyema, abscess) and pneumonia caused by drug-resistant strains.",
        "Ceftazidime-avibactam and Meropenem-vaborbactam should only be used only in patients with documented carbapenemase producing bacteria",
        "Procalcitonin may assist in determining duration of therapy"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Cefiderocol: FDA-approved for patients with complicated UTI due to cefiderocol susceptible bacteria and with limited or no alternative treatment options. In an open label randomized trial of cefiderocol vs Best Available Therapy (BAT) in patients with sepsis, pneumonia, bacteremia or cUTI, mortality at 28 days was 24.8% for cefiderocol pts. vs 18.4% for BAT pts (not statistically significant).",
        "Extended spectrum beta-lactamase (ESBL) producing strains should be considered resistant to all cephalosporins and are often co-resistant to all fluoroquinolones, TMP/SMX, and aminoglycosides.",
        "Fosfomycin IV is available in Europe for parenteral administration and is often active in vitro (Antimicrob Agents Chemother 54:526, 2010).",
        "Newer tetracyclines, Omadacycline (FDA-approved for treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia) and Eravacycline (FDA-approved only for treatment of intraabdominal infections) may be in vitro active against carbapenem-resistant strains, but clinical efficacy unknown.",
        "Ceftolozane-tazobactam is active in vitro against ESBL-producing strains; FDA-approved for treatment of complicated urinary tract, intra-abdominal infections, and hospital-acquired and ventilator-associated pneumonia. Outcomes in patients with ESBL-producing organisms were similar to those of the overall population of patients with these infections.",
        "Ceftazidime-avibactam active in vitro against serine carbapenemase-producing strains.",
        "Emergence of resistance documented in patients with microbiological failure (Clin Infect Dis 63:1615, 2016).",
        "Inactivated by bacteria producing some Oxa-carbapenemases (but Oxa-48 and Oxa-48-like producers are generally susceptible) and metallo-betalactamases",
        "In combination with Aztreonam active in vitro against metallo-betalactamase producing Enterobacteriaceae (Antimicrob Agents Chemother. 2017;61:pii: e02243-16) an observational study (Clin Infect Dis. 2021;72:1871) found this combination to be more effective than other treatment options.",
        "Meropenem-vaborbactam predictably active in presence of ESBLs and non-metallo (serine) carbapenemases.",
        "Not active against bacteria producing Oxa-carbapenemases (Oxa-48) and metallo-betalactamases.",
        "Review of treatment options for Oxa-48 and Oxa-48-like producing strains: Antimicrob Agents Chemother. 2022; 66:e0021622."
      ]
    }
  ]
}
